Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib With Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In

NCT05681195 is registered in ClinicalTrials.gov with Baptist Health South Florida as lead sponsor.

NCT NCT05681195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib With Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In
Lead sponsor
Baptist Health South Florida
Phase
Phase 2
Overall status
Recruiting
Start date
April 25, 2024
Completion date
February 28, 2033
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma, refractory cancer, relapsed cancer, secondary central nervous system lymphoma